Cargando…

oxLDL antibody inhibits MCP‐1 release in monocytes/macrophages by regulating Ca(2+)/K(+) channel flow

oxLDL peptide vaccine and its antibody adoptive transferring have shown a significantly preventive or therapeutic effect in atherosclerotic animal model. The molecular mechanism behind this is obscure. Here, we report that oxLDL induces MCP‐1 release in monocytes/macrophages through their TLR‐4 (Tol...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Jinyu, Zhou, Hui, Liu, Xianyan, Nilsson, Jan, Fredrikson, Gunilla Nordin, Zhao, Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5387129/
https://www.ncbi.nlm.nih.gov/pubmed/27995732
http://dx.doi.org/10.1111/jcmm.13033
_version_ 1782520884486995968
author Su, Jinyu
Zhou, Hui
Liu, Xianyan
Nilsson, Jan
Fredrikson, Gunilla Nordin
Zhao, Ming
author_facet Su, Jinyu
Zhou, Hui
Liu, Xianyan
Nilsson, Jan
Fredrikson, Gunilla Nordin
Zhao, Ming
author_sort Su, Jinyu
collection PubMed
description oxLDL peptide vaccine and its antibody adoptive transferring have shown a significantly preventive or therapeutic effect in atherosclerotic animal model. The molecular mechanism behind this is obscure. Here, we report that oxLDL induces MCP‐1 release in monocytes/macrophages through their TLR‐4 (Toll‐like receptor 4) and ERK MAPK pathway and is calcium/potassium channel‐dependent. Using blocking antibodies against CD36, TLR‐4, SR‐AI and LOX‐1, only TLR‐4 antibody was found to have an inhibitory effect and ERK MAPK‐specific inhibitor (PD98059) was found to have a dramatic inhibitory effect compared to inhibitors of other MAPK group members (p38 and JNK MAPKs) on oxLDL‐induced MCP‐1 release. The release of cytokines and chemokines needs influx of extracellular calcium and imbalance of efflux of potassium. Nifedipine, a voltage‐dependent calcium channel (VDCC) inhibitor, and glyburide, an ATP‐regulated potassium channel (K(+) (ATP)) inhibitor, inhibit oxLDL‐induced MCP‐1 release. Potassium efflux and influx counterbalance maintains the negative potential of macrophages to open calcium channels, and our results suggest that oxLDL actually induces the closing of potassium influx channel – inward rectifier channel (K(ir)) and ensuing the opening of calcium channel. ERK MAPK inhibitor PD98059 inhibits oxLDL‐induced Ca(2+)/K(ir) channel alterations. The interfering of oxLDL‐induced MCP‐1 release by its monoclonal antibody is through its FcγRIIB (CD32). Using blocking antibodies against FcγRI (CD64), FcγRIIB (CD32) and FcγRIII (CD16), only CD32 blocking antibody was found to reverse the inhibitory effect of oxLDL antibody on oxLDL‐induced MCP‐1 release. Interestingly, oxLDL antibody specifically inhibits oxLDL‐induced ERK MAPK activation and ensuing Ca(2+)/K(ir) channel alterations, and MCP‐1 release. Thus, we found a molecular mechanism of oxLDL antibody on inhibition of oxLDL‐induced ERK MAPK pathway and consequent MCP‐1 release.
format Online
Article
Text
id pubmed-5387129
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-53871292017-05-01 oxLDL antibody inhibits MCP‐1 release in monocytes/macrophages by regulating Ca(2+)/K(+) channel flow Su, Jinyu Zhou, Hui Liu, Xianyan Nilsson, Jan Fredrikson, Gunilla Nordin Zhao, Ming J Cell Mol Med Original Articles oxLDL peptide vaccine and its antibody adoptive transferring have shown a significantly preventive or therapeutic effect in atherosclerotic animal model. The molecular mechanism behind this is obscure. Here, we report that oxLDL induces MCP‐1 release in monocytes/macrophages through their TLR‐4 (Toll‐like receptor 4) and ERK MAPK pathway and is calcium/potassium channel‐dependent. Using blocking antibodies against CD36, TLR‐4, SR‐AI and LOX‐1, only TLR‐4 antibody was found to have an inhibitory effect and ERK MAPK‐specific inhibitor (PD98059) was found to have a dramatic inhibitory effect compared to inhibitors of other MAPK group members (p38 and JNK MAPKs) on oxLDL‐induced MCP‐1 release. The release of cytokines and chemokines needs influx of extracellular calcium and imbalance of efflux of potassium. Nifedipine, a voltage‐dependent calcium channel (VDCC) inhibitor, and glyburide, an ATP‐regulated potassium channel (K(+) (ATP)) inhibitor, inhibit oxLDL‐induced MCP‐1 release. Potassium efflux and influx counterbalance maintains the negative potential of macrophages to open calcium channels, and our results suggest that oxLDL actually induces the closing of potassium influx channel – inward rectifier channel (K(ir)) and ensuing the opening of calcium channel. ERK MAPK inhibitor PD98059 inhibits oxLDL‐induced Ca(2+)/K(ir) channel alterations. The interfering of oxLDL‐induced MCP‐1 release by its monoclonal antibody is through its FcγRIIB (CD32). Using blocking antibodies against FcγRI (CD64), FcγRIIB (CD32) and FcγRIII (CD16), only CD32 blocking antibody was found to reverse the inhibitory effect of oxLDL antibody on oxLDL‐induced MCP‐1 release. Interestingly, oxLDL antibody specifically inhibits oxLDL‐induced ERK MAPK activation and ensuing Ca(2+)/K(ir) channel alterations, and MCP‐1 release. Thus, we found a molecular mechanism of oxLDL antibody on inhibition of oxLDL‐induced ERK MAPK pathway and consequent MCP‐1 release. John Wiley and Sons Inc. 2016-12-20 2017-05 /pmc/articles/PMC5387129/ /pubmed/27995732 http://dx.doi.org/10.1111/jcmm.13033 Text en © 2016 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Su, Jinyu
Zhou, Hui
Liu, Xianyan
Nilsson, Jan
Fredrikson, Gunilla Nordin
Zhao, Ming
oxLDL antibody inhibits MCP‐1 release in monocytes/macrophages by regulating Ca(2+)/K(+) channel flow
title oxLDL antibody inhibits MCP‐1 release in monocytes/macrophages by regulating Ca(2+)/K(+) channel flow
title_full oxLDL antibody inhibits MCP‐1 release in monocytes/macrophages by regulating Ca(2+)/K(+) channel flow
title_fullStr oxLDL antibody inhibits MCP‐1 release in monocytes/macrophages by regulating Ca(2+)/K(+) channel flow
title_full_unstemmed oxLDL antibody inhibits MCP‐1 release in monocytes/macrophages by regulating Ca(2+)/K(+) channel flow
title_short oxLDL antibody inhibits MCP‐1 release in monocytes/macrophages by regulating Ca(2+)/K(+) channel flow
title_sort oxldl antibody inhibits mcp‐1 release in monocytes/macrophages by regulating ca(2+)/k(+) channel flow
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5387129/
https://www.ncbi.nlm.nih.gov/pubmed/27995732
http://dx.doi.org/10.1111/jcmm.13033
work_keys_str_mv AT sujinyu oxldlantibodyinhibitsmcp1releaseinmonocytesmacrophagesbyregulatingca2kchannelflow
AT zhouhui oxldlantibodyinhibitsmcp1releaseinmonocytesmacrophagesbyregulatingca2kchannelflow
AT liuxianyan oxldlantibodyinhibitsmcp1releaseinmonocytesmacrophagesbyregulatingca2kchannelflow
AT nilssonjan oxldlantibodyinhibitsmcp1releaseinmonocytesmacrophagesbyregulatingca2kchannelflow
AT fredriksongunillanordin oxldlantibodyinhibitsmcp1releaseinmonocytesmacrophagesbyregulatingca2kchannelflow
AT zhaoming oxldlantibodyinhibitsmcp1releaseinmonocytesmacrophagesbyregulatingca2kchannelflow